Prediction Potential of Serum miR-155 and miR-24 for Relapsing Early Breast Cancer
Jazyk angličtina Země Švýcarsko Médium electronic
Typ dokumentu časopisecké články
PubMed
28994735
PubMed Central
PMC5666798
DOI
10.3390/ijms18102116
PII: ijms18102116
Knihovny.cz E-zdroje
- Klíčová slova
- Ki-67, breast cancer, miR-155, miR-24, microRNA, relapse,
- MeSH
- antigen Ki-67 metabolismus MeSH
- časové faktory MeSH
- dospělí MeSH
- kohortové studie MeSH
- lidé středního věku MeSH
- lidé MeSH
- lokální recidiva nádoru diagnóza genetika MeSH
- longitudinální studie MeSH
- mikro RNA krev genetika MeSH
- multivariační analýza MeSH
- nádorové biomarkery krev genetika MeSH
- nádory prsu genetika MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- antigen Ki-67 MeSH
- mikro RNA MeSH
- MIRN155 microRNA, human MeSH Prohlížeč
- MIRN24 microRNA, human MeSH Prohlížeč
- nádorové biomarkery MeSH
Oncogenic microRNAs (oncomiRs) accumulate in serum due to their increased stability and thus serve as biomarkers in breast cancer (BC) pathogenesis. Four oncogenic microRNAs (miR-155, miR-19a, miR-181b, and miR-24) and one tumor suppressor microRNA (let-7a) were shown to differentiate between high- and low-risk early breast cancer (EBC) and reflect the surgical tumor removal and adjuvant therapy. Here we applied the longitudinal multivariate data analyses to stochastically model the serum levels of each of the oncomiRs using the RT-PCR measurements in the EBC patients (N = 133) that were followed up 4 years after diagnosis. This study identifies that two of the studied oncomiRs, miR-155 and miR-24, are highly predictive of EBC relapse. Furthermore, combining the oncomiR level with Ki-67 expression further specifies the relapse probability. Our data move further the notion that oncomiRs in serum enable not only monitoring of EBC but also are a very useful tool for predicting relapse independently of any other currently analyzed characteristics in EBC patients. Our approach can be translated into medical practice to estimate individual relapse risk of EBC patients.
BIOCEV 1st Faculty of Medicine Charles University Vestec 25250 Czech Republic
Comprehensive Cancer Centre Regional Hospital Liberec Liberec 46063 Czech Republic
Faculty of Mathematics and Physics Charles University Prague 18675 Czech Republic
Zobrazit více v PubMed
Mulrane L., Klinger R., McGee S.F., Gallagher W.M., O’Connor D.P. microRNAs: A new class of breast cancer biomarkers. Expert Rev. Mol. Diagn. 2014;14:347–363. doi: 10.1586/14737159.2014.901153. PubMed DOI
Zoon C.K., Starker E.Q., Wilson A.M., Emmert-Buck M.R., Libutti S.K., Tangrea M.A. Current molecular diagnostics of breast cancer and the potential incorporation of microRNA. Expert Rev. Mol. Diagn. 2009;9:455–467. doi: 10.1586/erm.09.25. PubMed DOI PMC
Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., Magri E., Pedriali M., Fabbri M., Campiglio M., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065–7070. doi: 10.1158/0008-5472.CAN-05-1783. PubMed DOI
Kim K., Chadalapaka G., Lee S.O., Yamada D., Sastre-Garau X., Defossez P.A., Park Y.Y., Lee J.S., Safe S. Identification of oncogenic microRNA-17–92/ZBTB4/specificity protein axis in breast cancer. Oncogene. 2012;31:1034–1044. doi: 10.1038/onc.2011.296. PubMed DOI PMC
Li S., Yang C., Zhai L., Zhang W., Yu J., Gu F., Lang R., Fan Y., Gong M., Zhang X., et al. Deep sequencing reveals small RNA characterization of invasive micropapillary carcinomas of the breast. Breast Cancer Res. Treat. 2012;136:77–87. doi: 10.1007/s10549-012-2166-6. PubMed DOI
Wu Q., Wang C., Lu Z., Guo L., Ge Q. Analysis of serum genome-wide microRNAs for breast cancer detection. Clin. Chim. Acta. 2012;413:1058–1065. doi: 10.1016/j.cca.2012.02.016. PubMed DOI
Kim S.J., Shin J.Y., Lee K.D., Bae Y.K., Sung K.W., Nam S.J., Chun K.H. MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C–C chemokine receptor type 7. Breast Cancer Res. 2012;14:R14. doi: 10.1186/bcr3098. PubMed DOI PMC
Song J., Bai Z., Han W., Zhang J., Meng H., Bi J., Ma X., Han S., Zhang Z. Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig. Dis. Sci. 2012;57:897–904. doi: 10.1007/s10620-011-1981-7. PubMed DOI
Zhao H., Shen J., Medico L., Wang D., Ambrosone C.B., Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS ONE. 2010;5:e13735. doi: 10.1371/journal.pone.0013735. PubMed DOI PMC
Sochor M., Basova P., Pesta M., Dusilkova N., Bartos J., Burda P., Pospisil V., Stopka T. Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer. 2014;14:448. doi: 10.1186/1471-2407-14-448. PubMed DOI PMC
Eichelser C., Flesch-Janys D., Chang-Claude J., Pantel K., Schwarzenbach H. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin. Chem. 2013;59:1489–1496. doi: 10.1373/clinchem.2013.205161. PubMed DOI
Kong W., He L., Richards E.J., Challa S., Xu C.X., Permuth-Wey J., Lancaster J.M., Coppola D., Sellers T.A., Djeu J.Y., et al. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 2014;33:679–689. doi: 10.1038/onc.2012.636. PubMed DOI PMC
Gasparini P., Lovat F., Fassan M., Casadei L., Cascione L., Jacob N.K., Carasi S., Palmieri D., Costinean S., Shapiro C.L., et al. Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proc. Natl. Acad. Sci. USA. 2014;111:4536–4541. doi: 10.1073/pnas.1402604111. PubMed DOI PMC
Bacci M., Giannoni E., Fearns A., Ribas R., Gao Q., Taddei M.L., Pintus G., Dowsett M., Isacke C.M., Martin L.A., et al. miR-155 drives metabolic reprogramming of ER+ breast cancer cells following long-term estrogen deprivation and predicts clinical response to aromatase inhibitors. Cancer Res. 2016;76:1615–1626. doi: 10.1158/0008-5472.CAN-15-2038. PubMed DOI
Ell B., Qiu Q., Wei Y., Mercatali L., Ibrahim T., Amadori D., Kang Y. The microRNA-23b/27b/24 cluster promotes breast cancer lung metastasis by targeting metastasis-suppressive gene prosaposin. J. Biol. Chem. 2014;289:21888–21895. doi: 10.1074/jbc.M114.582866. PubMed DOI PMC
Farazi T.A., Horlings H.M., Ten Hoeve J.J., Mihailovic A., Halfwerk H., Morozov P., Brown M., Hafner M., Reyal F., van Kouwenhove M., et al. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res. 2011;71:4443–4453. doi: 10.1158/0008-5472.CAN-11-0608. PubMed DOI PMC
Bisso A., Faleschini M., Zampa F., Capaci V., De Santa J., Santarpia L., Piazza S., Cappelletti V., Daidone M., Agami R., et al. Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle. 2013;12:1679–1687. doi: 10.4161/cc.24757. PubMed DOI PMC
Serpico D., Molino L., Di Cosimo S. microRNAs in breast cancer development and treatment. Cancer Treat. Rev. 2014;40:595–604. doi: 10.1016/j.ctrv.2013.11.002. PubMed DOI
Liang K., Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13–22. doi: 10.1093/biomet/73.1.13. DOI
Hudecova S., Pesta M. Modeling dependencies in claims reserving with GEE. Insur. Math. Econ. 2013;53:786–794. doi: 10.1016/j.insmatheco.2013.09.018. DOI
Assessing the Role of MicroRNAs in Predicting Breast Cancer Recurrence-A Systematic Review
